Dance Biopharm unveils positive Phase 2 trial data for inhaled insulin
Category: #health  By Mateen Dalal  Date: 2019-06-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Dance Biopharm unveils positive Phase 2 trial data for inhaled insulin

The new data further supports the potential of Dance 501 inhaled insulin in Type 2 diabetes patients

Dance Biopharm Holdings, Inc has recently presented Phase 2 Samba 04 clinical study results for its preservative free inhaled human insulin, Dance 501, for the treatment of Type 2 diabetes. Dance Biopharm is a privately-owned clinical stage biopharma company fully focused on the development of a new soft mist inhalable biologic formulations for those people suffering from chronic diseases.

Seemingly, in the results Dance 501 showed a faster onset of action for as compared to similar doses of subcutaneously administered insulin lispro. These findings were to be presented at the 79th Scientific Sessions of the American Diabetes Association, being organized in San Francisco.

According to Anne Whitaker, the chief executive officer of Dance Biopharm, the company’s presentation at ADA underscores ongoing commitment of Dance to develop advanced and patient-focused inhaled therapies that result to better health outcomes for people suffering with chronic diseases like diabetes.

Whitaker said that the new data further supports the potential of Dance 501, inhaled preservative free human inhaled insulin, which is an alternate treatment to injectable insulin for diabetes. These data determine the outstanding performance of soft mist inhaler platform and encourages the company to swiftly progress the development of its innovative soft mist biologics portfolio as treatments for chronic and severe diseases, Whitaker mentioned.

Sources familiar with the matter informed that this Phase 2 clinical trial, Samba 04, was designed as an open label, crossover, randomized, and active-comparator-controlled study that recruited 24 subjects with type 2 diabetes presently receiving metformin or insulin therapy. Each patient got three doses of subcutaneous insulin lispro and three doses of inhaled Dance 501 under medical administration or supervision.

Apparently, doses administered were 12, 24 and 48 U for both lispro and Dance 501. Each patient received all 6 doses during 6 visits that occurred 3 to 17 days apart. Using the automated glucose clamp method, insulin action was measured over a 10-hour period following dosing.

 

Source Credit: https://www.dancebiopharm.com/investors-and-media/press-releases/detail/18/dance-biopharm-presents-encouraging-data-from-phase-2

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...

Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
By Mateen Dalal

Mojocare, a wellness and health startup has reportedly raised USD 20.6 million in a Series A round of funding which was led by B Capital Group and saw participation from existing investors including Sequoia India’s Surge, Better Capital, and Ch...

Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
By Mateen Dalal

Bangalore-based Exponent Energy has reportedly secured USD 13 million in a Series A funding round which was spearheaded by Lightspeed Venture Partners. The round also saw participation from existing investors such as 3one4 Capital, YourNest VC, and A...